We showed that a functional crosstalk between GR and MR exists in myeloma and that a targeting hereof with ligands warrants further investigation of its potential therapeutic benefit in terms of efficacy, safety and the possibility to reduce the GC-dose. The gene discussed is NR3C1; the disease is plasma cell myeloma.